Blau syndrome is a monogenic inflammatory disease that classically involves the triad of arthritis, uveitis, and dermatitis. This syndrome is the familial form of early-onset sarcoidosis, and the two entities have some shared mutations in the NOD2 gene. Blau syndrome was first described in 1985 and is characterized predominantly by granulomas in the affected areas. Management remains a challenge, as Blau syndrome is rare and evidence is lacking. Here, we describe in greater detail the clinical features, pathophysiology, diagnosis, management, and prognosis of Blau syndrome.
KeywordsBlau Jabs Sarcoidosis Granuloma Arthritis Uveitis NOD2 NACHT CARD15
- 27.Milman N, et al. Favourable effect of TNF-alpha inhibitor (infliximab) on Blau syndrome in monozygotic twins with a de novo CARD15 mutation. APMIS. 2006;114(12):912–9. https://doi.org/10.1111/j.1600-0463.2006.apm_522.x.CrossRefPubMedGoogle Scholar
- 28.Otsubo Y, et al. A long-term follow-up of Japanese mother and her daughter with Blau syndrome: effective treatment of anti-TNF inhibitors and useful diagnostic tool of joint ultrasound examination. Mod Rheumatol. 2017;27(1):169–73. https://doi.org/10.3109/14397595.2014.964388.CrossRefPubMedGoogle Scholar
- 29.Aróstegui JI, et al. NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum. 2007;56(11):3805–13. https://doi.org/10.1002/art.22966.CrossRefPubMedGoogle Scholar